Tesamorelin

Description

Overview

Tesamorelin is a fully synthetic 44-residue analog of human growth hormone-releasing hormone, GHRH(1-44), distinguished from the native sequence by an N-terminal trans-3-hexenoyl acylation on the Tyr1 alpha-amino group. This structural modification is intended to increase resistance to enzymatic cleavage relative to unmodified GHRH, and is a frequent point of interest in structure-stability investigations. G Peptide Labs supplies Tesamorelin as a lyophilized powder intended strictly for in-vitro and preclinical laboratory research. It is not a drug, supplement, or food, and is not intended for human or veterinary use.

• Full-length GHRH(1-44) scaffold with N-terminal lipophilic acyl modification
• Supplied lyophilized for reconstitution in a controlled laboratory setting
• Every lot accompanied by third-party analytical documentation

Research Context

Tesamorelin is widely used as a reference GHRH-analog tool compound in studies of the somatotropic axis. In published preclinical and clinical research literature, investigators have examined how GHRH-analog exposure relates to endogenous growth hormone (GH) pulsatility, downstream insulin-like growth factor 1 (IGF-1) signaling, and visceral adipose tissue dynamics in animal models and controlled study populations. Within a laboratory setting, researchers commonly employ Tesamorelin to probe GHRH-receptor engagement, secretagogue pharmacology, and comparative behavior against other GH-axis analogs. All such work described here refers to in-vitro systems, animal models, and controlled research settings only.

Mechanism of Interest

The GHRH receptor (GHRH-R) is a class B G-protein-coupled receptor characterized on somatotroph cell models of the anterior pituitary. In receptor-level research, agonist binding is associated with adenylate cyclase activation and downstream cAMP accumulation, a cascade frequently used as a readout in in-vitro signaling assays. Because Tesamorelin retains the full GHRH(1-44) recognition sequence, it is studied as a probe of this pathway and of the GH/IGF-1 signaling cascade in hepatocyte and cell-culture models. Researchers frequently contrast GHRH-R-mediated pathways with ghrelin/GHS-receptor mechanisms used by unrelated secretagogues.

Specifications

• Compound: Tesamorelin (GHRH(1-44) analog, trans-3-hexenoyl modified)
• CAS number: 218949-48-5 (free base); 901758-09-6 (acetate salt)
• Molecular formula: C221H366N72O67S
• Molecular weight: 5135.86 g/mol (average)
• Purity: greater than or equal to 99% by HPLC (lot-specific value on COA)
• Physical form: White to off-white lyophilized powder
• Identity confirmation: Mass spectrometry (lot-specific)

Handling, Reconstitution & Storage

Handling should follow standard laboratory practice for research peptides, including gloves, eye protection, and work in an appropriate controlled environment. As received, the lyophilized powder is best stored sealed and desiccated at -20 degrees C, where it is generally stable for extended periods.

• Allow the sealed vial to equilibrate to room temperature before opening to limit condensation
• Reconstitute with a suitable sterile solvent such as bacteriostatic or sterile water, directing the stream against the vial wall rather than onto the powder
• Swirl gently to dissolve; avoid vigorous shaking, which can shear the peptide
• Aliquot reconstituted solution to minimize freeze-thaw cycles; store working solutions cold and use within a short window
• Keep protected from light and repeated temperature fluctuation

Quality & Verification

Each lot of Tesamorelin is released with third-party analytical support so that receiving laboratories can independently confirm identity and purity. The certificate of analysis (COA) reports the HPLC purity value and mass-spectrometry identity data specific to the lot shipped. Researchers are encouraged to match the lot number on the vial to the COA before beginning any protocol and to retain the documentation for laboratory records and reproducibility.

• Lot-specific HPLC purity and MS identity data
• Independent, third-party analytical verification
• Consistent lyophilization and fill for lot-to-lot reproducibility

Research Use Only. This product is intended exclusively for in-vitro and laboratory research. It is not for human or animal consumption and is not a drug, cosmetic, or therapeutic agent. No statement here should be interpreted as a medical or health claim.

Selected Research

Peer-reviewed references provided for scientific context; they describe laboratory and preclinical findings only.

1. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S, 2007. PMID: 18057338
2. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology and Metabolism Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S, 2010. PMID: 20554713
3. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. The Journal of Clinical Endocrinology and Metabolism Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK, 2011. PMID: 20943777
4. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice Badran AS, Helal A, Shata KS, Ayesh H, 2026. PMID: 41545261